Cytosorbents Corporation (CTSO)
| Previous Close | 0.8100 |
| Open | 0.8318 |
| Bid | 0.8088 x 100 |
| Ask | 0.8799 x 100 |
| Day's Range | 0.8100 - 0.8642 |
| 52 Week Range | 0.7820 - 4.2900 |
| Volume | |
| Avg. Volume | 100,606 |
| Market Cap | 45.655M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.70 |
GlobeNewswireCytoSorbents to Report First Quarter 2024 Operating and Financial Results
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024. CytoSorbents’ management will host a live conference call and presentation webcast and a question and answer session starting at 4:30PM EDT the same day. Webcast D
- GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a
Simply Wall St.These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
The analysts covering Cytosorbents Corporation ( NASDAQ:CTSO ) delivered a dose of negativity to shareholders today, by...
